<?xml version="1.0" ?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" 
 xmlns:mml="http://www.w3.org/1998/Math/MathML">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text>
		<front/>
		<body/>
		<back>
<listBibl>
	<bibl>. <author>Rapezzi C, Quarta CC, Riva L, et al.</author> <title level="a">Transthyretin-related amyloidoses and the heart: a clinical overview</title>. <title level="j">Nat Rev Cardiol</title> <date>2010</date>; <biblScope unit="volume">7</biblScope>: <biblScope unit="page">398-408</biblScope>.</bibl>
	<bibl>. <author>Ruberg FL, Berk JL</author>. <title level="a">Transthyretin (TTR) cardiac amyloidosis</title>. <title level="j">Circulation</title> <date>2012</date>; <biblScope unit="volume">126</biblScope>: <biblScope unit="page">1286-300</biblScope>.</bibl>
	<bibl>. <author>Maurer MS, Hanna M, Grogan M, et al.</author> <title level="a">Genotype and phenotype of trans-thyretin cardiac amyloidosis: THAOS</title> (<title level="s">Transthyretin Amyloid Outcome Survey).</bibl>
	<bibl><title level="j">J Am Coll Cardiol</title> <date>2016</date>; <biblScope unit="volume">68</biblScope>: <biblScope unit="page">161-72</biblScope>.</bibl>
	<bibl>. <author>Gillmore JD, Maurer MS, Falk RH, et al.</author> <title level="a">Nonbiopsy diagnosis of cardiac transthyre-tin amyloidosis</title>. <title level="j">Circulation</title> <date>2016</date>; <biblScope unit="volume">133</biblScope>: <biblScope unit="page">2404-12</biblScope>.</bibl>
	<bibl>. <author>Castano A, Haq M, Narotsky DL, et al.</author> <title level="a">Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: pre-dicting survival for patients with ATTR cardiac amyloidosis</title>. <title level="j">JAMA Cardiol</title> <date>2016</date>; <biblScope unit="volume">1</biblScope>: <biblScope unit="page">880-9</biblScope>.</bibl>
	<bibl>. <author>González-López E, Gallego-Delgado M, Guzzo-Merello G, et al.</author> <title level="a">Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection frac-tion</title>. <title level="j">Eur Heart J</title> <date>2015</date>; <biblScope unit="volume">36</biblScope>: <biblScope unit="page">2585-94</biblScope>.</bibl>
	<bibl>. <author>Castaño A, Narotsky DL, Hamid N, et al.</author> <title level="a">Unveiling transthyretin cardiac amy-loidosis and its predictors among elderly patients with severe aortic stenosis under-going transcatheter aortic valve replace-ment</title>. <title level="j">Eur Heart J</title> <date>2017</date>; <biblScope unit="volume">38</biblScope>: <biblScope unit="page">2879-87</biblScope>.</bibl>
	<bibl>. <author>Damy T, Costes B, Hagège AA, et al.</author> <title level="a">Prevalence and clinical phenotype of he-reditary transthyretin amyloid cardiomy-opathy in patients with increased left ven-tricular wall thickness</title>. <title level="j">Eur Heart J</title> <date>2016</date>; <biblScope unit="volume">37</biblScope>: <biblScope unit="page">1826-34</biblScope>.</bibl>
	<bibl>. <author>Grogan M, Scott CG, Kyle RA, et al.</author> <title level="a">Natural history of wild-type transthyre-tin cardiac amyloidosis and risk stratifi-Tafamidis for Tr ansthyretin Amyloid Cardiomyopathy cation using a novel staging system</title>. <title level="j">J Am Coll Cardiol</title> <date>2016</date>; <biblScope unit="volume">68</biblScope>: <biblScope unit="page">1014-20</biblScope>.</bibl>
	<bibl>. <author>Gillmore JD, Damy T, Fontana M, et al.</author> <title level="a">A new staging system for cardiac trans-thyretin amyloidosis</title>. <title level="j">Eur Heart J 2017 Oc-tober</title> <biblScope unit="volume">18</biblScope> (Epub ahead of print).</bibl>
	<bibl>. <author>Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C</author>. <title level="a">Structure of prealbumin: sec-ondary, tertiary and quaternary interac-tions determined by Fourier refinement at 1</title>.</bibl>
	<bibl><author>A.</author> <title level="j">J Mol Biol</title> <date>1978</date>; <biblScope unit="volume">121</biblScope>: <biblScope unit="page">339-56</biblScope>.</bibl>
	<bibl>. <author>Monaco HL, Rizzi M, Coda A</author>. <title level="a">Struc-ture of a complex of two plasma proteins: transthyretin and retinol-binding protein</title>. <title level="j">Science</title> <date>1995</date>; <biblScope unit="volume">268</biblScope>: <biblScope unit="page">1039-41</biblScope>.</bibl>
	<bibl>. <author>Colon W, Kelly JW</author>. <title level="a">Partial denatur-ation of transthyretin is sufficient for amyloid fibril formation in vitro</title>. <title level="j">Bio-chemistry</title> <date>1992</date>; <biblScope unit="volume">31</biblScope>: <biblScope unit="page">8654-60</biblScope>.</bibl>
	<bibl>. <author>Castaño A, Drachman BM, Judge D, Maurer MS</author>. <title level="a">Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs</title>. <title level="j">Heart Fail Rev</title> <date>2015</date>; <biblScope unit="volume">20</biblScope>: <biblScope unit="page">163-78</biblScope>.</bibl>
	<bibl>. <author>Hammarström P, Schneider F, Kelly JW</author>. <title level="a">Trans-suppression of misfolding in an amyloid disease</title>. <title level="j">Science</title> <date>2001</date>; <biblScope unit="volume">293</biblScope>: <biblScope unit="page">2459-62</biblScope>.</bibl>
	<bibl>. <author>Coelho T, Merlini G, Bulawa CE, et al.</author> <title level="a">Mechanism of action and clinical applica-tion of tafamidis in hereditary transthyre-tin amyloidosis</title>. <title level="j">Neurol Ther</title> <date>2016</date>; <biblScope unit="volume">5</biblScope>: <biblScope unit="page">1-25</biblScope>.</bibl>
	<bibl>. <author>Maurer MS, Grogan DR, Judge DP, et al.</author> <title level="a">Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes</title>. <title level="j">Circ Heart Fail</title> <date>2015</date>; <biblScope unit="volume">8</biblScope>: <biblScope unit="page">519-26</biblScope>.</bibl>
	<bibl>. <author>Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS</author>. <title level="a">TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis</title>. <title level="j">Circ Heart Fail</title> <date>2018</date>; <biblScope unit="volume">11</biblScope>(<biblScope unit="issue">4</biblScope>): <biblScope unit="page">e004769</biblScope>.</bibl>
	<bibl>. <author>Maurer MS, Elliott P, Merlini G, et al.</author> <title level="a">Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)</title>. <title level="j">Circ Heart Fail</title> <date>2017</date>; <biblScope unit="volume">10</biblScope>(<biblScope unit="issue">6</biblScope>): <idno>e003815. 20</idno>. <title level="a">ATS Committee on Proficiency Stan-dards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test</title>. <title level="j">Am J Respir Crit Care Med</title> <date>2002</date>; <biblScope unit="volume">166</biblScope>: <biblScope unit="page">111-7</biblScope>.</bibl>
	<bibl>. <author>Green CP, Porter CB, Bresnahan DR, Spertus JA</author>. <title level="a">Development and evaluation of the Kansas City Cardiomyopathy Ques-tionnaire: a new health status measure for heart failure</title>. <title level="j">J Am Coll Cardiol</title> <date>2000</date>; <biblScope unit="volume">35</biblScope>: <biblScope unit="page">1245-55</biblScope>.</bibl>
	<bibl>. <author>Finkelstein DM, Schoenfeld DA</author>. <title level="a">Com-bining mortality and longitudinal mea-sures in clinical trials</title>. <title level="j">Stat Med</title> <date>1999</date>; <biblScope unit="volume">18</biblScope>: <biblScope unit="page">1341-54</biblScope>.</bibl>
	<bibl>. <title level="a">Wolfinger RD. An example of using mixed models and PROC MIXED for lon-gitudinal data</title>. <title level="j">J Biopharm Stat</title> <date>1997</date>; <biblScope unit="volume">7</biblScope>: <biblScope unit="page">481-500</biblScope>.</bibl>
	<bibl>. <author>Pocock SJ, Ariti CA, Collier TJ, Wang D</author>. <title level="a">The win ratio: a new approach to the analysis of composite endpoints in clini-cal trials based on clinical priorities</title>. <title level="j">Eur Heart J</title> <date>2012</date>; <biblScope unit="volume">33</biblScope>: <biblScope unit="page">176-82</biblScope>.</bibl>
	<bibl>. <author>Coelho T, Maia LF, Martins da Silva A, et al.</author> <title level="a">Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial</title>. <title level="j">Neurology</title> <date>2012</date>; <biblScope unit="volume">79</biblScope>: <biblScope unit="page">785-92</biblScope>.</bibl>
	<bibl>. <author>Groenning BA, Nilsson JC, Sonder-gaard L, Fritz-Hansen T, Larsson HB</author>, <title level="a">Hil-debrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure</title>. <title level="j">J Am Coll Cardiol</title> <date>2000</date>; <biblScope unit="volume">36</biblScope>: <biblScope unit="page">2072-80</biblScope>.</bibl>
	<bibl>. <author>Solomon SD, Foster E, Bourgoun M, et al.</author> <title level="a">Effect of cardiac resynchronization therapy on reverse remodeling and rela-tion to outcome: Multicenter Automatic Defibrillator Implantation Trial: cardiac resynchronization therapy</title>. <title level="j">Circulation</title> <date>2010</date>; <biblScope unit="volume">122</biblScope>: <biblScope unit="page">985-92</biblScope>.</bibl>
	<bibl><author>. Konstam MA, Rousseau MF, Kronen-berg MW, et al.</author> <title level="a">Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventric-ular dysfunction in patients with heart failure</title>. <title level="j">Circulation</title> <date>1992</date>; <biblScope unit="volume">86</biblScope>: <biblScope unit="page">431-8</biblScope>.</bibl>
	<bibl>. <author>Sultan MB, Gundapaneni B, Schu-macher J, Schwartz JH</author>. <title level="a">Treatment with tafamidis slows disease progression in early-stage transthyretin cardiomyopathy</title>. <title level="j">Clin Med Insights Cardiol</title> <date>2017</date>; <biblScope unit="volume">11</biblScope>: <biblScope unit="page">1179546817730322</biblScope>.</bibl>
	<bibl>. <author>Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L</author>. <title level="a">Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid poly-neuropathy: additional supportive analy-ses from the pivotal trial</title>. <title level="j">Amyloid</title> <date>2017</date>; <biblScope unit="volume">24</biblScope>: <biblScope unit="page">30-6</biblScope>.</bibl>
	<bibl>. <author>Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS</author>. <title level="a">(99m)Tc-pyrophosphate scintigraphy for differen-tiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses</title>. <title level="j">Circ Car-diovasc Imaging</title> <date>2013</date>; <biblScope unit="volume">6</biblScope>: <biblScope unit="page">195-201</biblScope>.</bibl>
	<bibl>. <author>Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL</author>. <title level="a">Can 99m Tc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloido-sis?</title> <title level="j">JACC Cardiovasc Imaging</title> <date>2017</date>; <biblScope unit="volume">10</biblScope>: <biblScope unit="page">713-4</biblScope>.</bibl>
	<bibl>. <author>Glaudemans AW, van Rheenen RW, van den Berg MP, et al.</author> <title level="a">Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloido-sis</title>. <title level="j">Amyloid</title> <date>2014</date>; <biblScope unit="volume">21</biblScope>: <biblScope unit="page">35-44</biblScope>.</bibl>
	<bibl>. <author>Galat A, Rosso J, Guellich A, et al.</author> <title level="a">Usefulness of (99m)Tc-HMDP scintigra-phy for the etiologic diagnosis and prog-nosis of cardiac amyloidosis</title>. <title level="j">Amyloid</title> <date>2015</date>; <biblScope unit="volume">22</biblScope>: <biblScope unit="page">210-20</biblScope>.</bibl>

		</listBibl>
	</back>
	</text>
</TEI>
